Akero Therapeutics, Inc. (AKRO) NASDAQ

44.86

-0.99(-2.16%)

Updated at March 13 04:00PM

Currency In USD

Akero Therapeutics, Inc.

Address

601 Gateway Boulevard

South San Francisco, CA 94080

United States of America

Phone

650 487 6488

Sector

Healthcare

Industry

Biotechnology

Employees

63

First IPO Date

June 20, 2019

Key Executives

NameTitlePayYear Born
Dr. Andrew Cheng M.D., Ph.D.President, Chief Executive Officer & Director1.04M1967
Dr. Jonathan M. Young J.D., Ph.D.Co-Founder, Executive Vice President, Chief Operating Officer & Secretary672,3531970
Mr. William R. White J.D.Executive Vice President, Chief Financial Officer, Treasurer & Head of Corporate Development678,0631974
Ms. Catriona YaleExecutive Vice President & Chief Development Officer678,0631972
Dr. Timothy Rolph Ph.D.Co-Founder & Chief Scientific Officer722,3151954
Mr. John J. SchembriSenior Vice President & Head of Finance01962
Mr. Thomas RossSenior Vice President & Head of Legal0N/A
Mr. Patrick LamySenior Vice President of Commercial Strategy01973
Mr. Scott A. GangloffChief Technical Officer01974

Description

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.